

## Review

# Protein phosphatases and their potential implications in neuroprotective processes

C. E. Gee and I. M. Mansuy\*

Brain Research Institute, University of Zürich, Department of Biology, Swiss Federal Institute of Technology, Winterthurerstrasse 190, 8057 Zürich (Switzerland), Fax: +41 44 6353303, e-mail: mansuy@hifo.unizh.ch

Received 8 January 2005; received after revision 3 March 2005; accepted 14 March 2005

**Abstract.** Several neurological disorders such as stroke, amyotrophic lateral sclerosis and epilepsy result from excitotoxic events and are accompanied by neuronal cell death. These processes engage multiple signalling pathways and recruit numerous molecular components, in particular several families of protein kinases and protein phosphatases. While many investigations have examined the importance of protein kinases in excitotoxicity, protein phosphatases have not been well studied in this context.

However, recent advances in understanding the functions of protein phosphatases have suggested that they may play a neuroprotective role. In this review, we summarize some of the recent findings that illustrate the pleiotropic and complex functions of tyrosine and serine/threonine protein phosphatases in the cascade of events leading to neuronal cell death, and highlight their potential intervention in limiting the extent of neuronal death.

**Key words.** Tyrosine phosphatase; serine/threonine phosphatase; excitotoxicity; neuroprotection; NMDA receptor.

## Introduction

Neurological and cognitive disorders associated with degeneration of brain tissue represent a major challenge for clinicians and research scientists because of the limited potential for de novo production of nerve cells in the mature organism. Although the mechanisms of degeneration and death of brain cells are not fully understood, one of their features appears to be linked to aberrant phosphorylation of proteins in these cells. Abnormal phosphorylation has been associated with excitotoxicity, a process that generally results from the excessive stimulation of calcium-permeable glutamate receptors followed by massive calcium influx into cells, inappropriate activation of calcium-dependent enzymes, production of free radicals, alteration of mitochondrial functions and ultimately initiation of cell death. Neuronal loss due to excitotoxicity may contribute to the pathophysiology of chronic neurodegenerative illnesses such as Alzheimer's disease,

amyotrophic lateral sclerosis, Parkinson's disease and Huntington's disease [1–4].

Clearly, multiple pathways are affected in response to perturbed calcium homeostasis. This represents a major complication for the development of potential therapeutic intervention. For instance, interfering with one of the most upstream molecular components of the cascade such as glutamate receptors in an attempt to hinder the whole cascade has proven unsuccessful. The development of specific antagonists acting on neuronal glutamate receptors has not provided the expected beneficial effect for treatment because of the multiplicity and severity of their side effects. Advances in the identification and understanding of pathways implicated in excitotoxicity and neuronal cell death have, however, raised the hope that targeting intracellular transduction elements downstream from glutamate receptors may prove a useful strategy for alleviating or attenuating neuronal injury. Of particular interest in this respect are protein phosphatases, which despite their demonstrated implication in excitotoxicity may play an important role in the mech-

\* Corresponding author.

anisms that limit brain damage and mediate neuroprotection. In this review, we summarize recent findings suggesting the involvement of tyrosine and serine/threonine protein phosphatases in neuroprotection, with a focus on experimental findings derived from models of brain injury such as transient or global cerebral ischemia, glutamate excitotoxicity and hypoxia. We try to illustrate the pleiotropic functions and complexity of the mechanisms that these molecules are involved in during these processes (see table 1).

### Tyrosine and serine/threonine protein phosphatases

Tyrosine and serine/threonine protein phosphatases are highly abundant proteins present in many cellular compartments of mammalian cells. Together with protein kinases, they set the phosphorylation state of signalling and effector proteins and thereby play a large role in controlling cellular responses. The balance between protein phosphatases and kinases is essential for the regulation of cellular signalling, and inappropriate or defective phosphatase or kinase activity leads to aberrant patterns of

phosphorylation. Dysregulated phosphorylation/dephosphorylation underlies numerous human diseases, including but not restricted to diabetes [5], cancer [6–8], autism [9], Alzheimer's disease [10], Lafora's disease [11] and Parkinson's disease [12].

### Tyrosine phosphatases

To date, 107 genes encoding tyrosine phosphatases have been identified in the human genome [13, 14]. All share the ability to hydrolyze p-nitrophenyl phosphate, are inhibited by vanadate and are insensitive to okadaic acid [15, 16]. In addition to their ability to dephosphorylate phosphotyrosine residues, a subset of tyrosine phosphatases can also dephosphorylate phosphoserine or phosphothreonine residues. These dual-specificity phosphatases may also target messenger RNA (mRNA), phospholipids and phosphoinositides in addition to phosphoproteins. Membrane-spanning phosphotyrosine-specific phosphatases are known collectively as receptor-like protein tyrosine phosphatases, whereas others lack membrane-spanning domains and are found in the cytoplasm. Except for the Eya (eyes absent) tyrosine phosphatases,

Table 1. Overview of potential neuroprotection conferred by Tyr and Ser/Thr protein phosphatases.

Protein phosphatase	Model tested for neuroprotection	(Hypothetical/proposed) neuroprotective mechanisms	Ref.
<b>Tyrosine phosphatases</b>			
SHP1	permanent focal cerebral ischemia cochlear ablation	reduction of glial activation reduction of proinflammatory cytokines/ enhancement of anti-inflammatory cytokines	[72, 73]
SHP2	focal cerebral ischemia/reperfusion nitric oxide toxicity	enhancement of neurotrophin signalling	[67, 68]
PTP $\alpha$ *	not tested	dephosphorylation and enhancement of potassium channel Kv1.2 currents * potential neurotoxic role: activation of Src family kinases and enhanced currents through NMDA receptors	[74, 75, 78]
STEP	not tested	dephosphorylation of Src family kinases reduction of currents through NMDA receptors	[52, 55]
PTEN*	promotes glutamate excitotoxicity promotes focal ischemic damage	* increases Akt activity, * increases currents through NMDA receptors	[80, 82]
<b>Serine/Threonine phosphatases</b>			
Calcineurin (PP2B)*	transient forebrain ischemia	dephosphorylation of the NR2A subunit of the NMDA receptor, desensitization of NMDA receptor	[86, 87]
	hypoxia/aglycemia in brain slices glutamate treatment of mouse primary cortical cultures	interaction with Bcl-2, dephosphorylation of IP <sub>3</sub> -Rs nicotine-mediated inactivation of L-type calcium-channels	[88, 89] [92]
PP1	hypoxia in epithelial cells	dephosphorylation, ubiquitination and degradation of CREB	[84]

\* Activity of these phosphatases may exacerbate neurotoxic processes.




Figure 1. Schematic representation of pathways associated with excitotoxic events. Excessive glutamate overactivates glutamate receptors leading to increased intracellular Ca<sup>2+</sup> ([Ca<sup>2+</sup>]<sub>i</sub>) and the activation of multiple downstream pathways. Protein phosphatases may intervene in several parts of these pathways to activate or inhibit different substrates. See text for more detail. NOS nitric oxide synthase, VDCC voltage-dependent Ca<sup>2+</sup> channel, ASIC acid sensing ion channel, GP G protein, PLC phospholipase C.

which use a different catalytic process requiring an aspartic acid [17], dephosphorylation generally begins when a protein with a phosphorylated tyrosine residue enters the active site of the phosphatase. Then the phosphoryl group is transferred to a key cysteine residue by nucleophilic attack, after which the tyrosine is protonated and ejected from the active site. The thiol intermediate on the cysteine residue is then hydrolysed, and the phosphatase is returned to its resting state [18, 19].

Target specificity of tyrosine phosphatases is ensured by multiple molecular strategies. One mechanism relies on the property that different tyrosine phosphatases preferentially recognize certain phosphopeptides. Specificity is also achieved by cell-type and organelle-specific expression of individual PTPs (protein tyrosine phosphatases). In addition, most tyrosine phosphatases have multiple domains, which may be involved in target recognition and in localization to particular cellular compartments and complexes of protein assemblies. For example, SHP-1 and SHP-2 possess Src homology 2 (SH2) domains, LAR and RPTP have immunoglobulin- and fibronectin-like domains, and the Eya members contain DNA recognition sequences. The presence or exclusion of particular tyrosine phosphatases in protein complexes is critical for their signalling specificity. For example, CD45, which is found in all hematopoietic cells, can activate Src family tyrosine kinases by dephosphorylating the inhibitory site or can inhibit them by dephosphorylating the activation site depending on the cell type.

The mechanism whereby pathway specificity is determined appears to be the co-localization of or exclusion of CD45 from the receptor/Src signalling complex [20].

### Serine/threonine phosphatases

Like PTPs, Ser/Thr protein phosphatases represent a diverse family, are expressed in many cell types and cellular compartments, and are regulated via several mechanisms [21, 22]. They are classified into PPP and PPM families defined by distinct amino acid sequence and 3-dimensional structure. The major phosphatases in the PPP family are PP1, PP2A and PP2B (calcineurin), and the PPM family includes PP2C. PP1, PP2A and PP2B are composed of catalytic and regulatory subunits, with each subunit type being expressed in several isoforms by distinct genes and/or alternative splicing. By contrast, PP2C exists as a monomer devoid of regulatory subunits. Regulatory subunits generally have multiple functions, including controlling catalytic activity, subcellular localization and substrate-specificity of the protein phosphatase. The marked molecular diversity brought about by the varied subunit composition is further enhanced by the requirement of covalent modifications on some subunits and/or the dependence on specific ions. For instance, PP2B requires Ca<sup>2+</sup> and calmodulin for full activity, whereas PP2C needs Mg<sup>2+</sup> or Mn<sup>2+</sup> [21, 22]. The specificity and activity of Ser/Thr protein phosphatases are largely controlled by interacting partners and

scaffolding proteins. These proteins act as regulatory subunits that compartmentalize phosphatase subunits in discrete subcellular locations and bring them into close proximity with target substrates [23]. They thereby confer spatial control to their catalytic activity. In the brain, localization of protein phosphatases to synaptic structures such as the postsynaptic density (PSD) is critical for neuronal signalling. For example, the  $\gamma 1$  subunit of PP1 is specifically concentrated in dendrites and presynaptic boutons in part through attachment to the anchoring protein *yotiao* localized in these compartments. In addition to compartmentalizing protein phosphatases, anchoring proteins also have inhibitory or activating actions towards different substrates. For instance, A-kinase anchoring proteins (AKAPs) belong to a family of proteins that can anchor PP2B and protein kinase A (PKA) to N-methyl-D-aspartate (NMDA) receptors, and therefore control the activity of this complex. Likewise, spinophilin is a binding protein containing a PDZ domain (postsynaptic-density-protein/disc-large/zo-1 domain) that mediates the association of PP1 with actin and neurotransmitter receptors such as the D2 dopamine (DA) receptor [24], the alpha adrenergic receptor [25] and p70S6 kinase (p70S6K) [26]. Other interacting proteins have also been found to have dual functions depending on their partner. Inhibitor 1/PP2A and inhibitor 2/PP2A are two proteins known to inhibit PP2A that can also stimulate PP1 activity in vitro [unlike inhibitor-1 (I1), which is a PP1 inhibitor] [27].

In addition to anchoring proteins, specific endogenous activators/inhibitors exist that contribute to regulating phosphatase activity. Their nature and mode of action may vary depending on cell type and brain structure. I1 and dopamine and cyclic AMP (cAMP)-regulated phosphoprotein Mr 32000 (DARPP-32) are two PP1 inhibitors (different from inhibitor 1/PP2A above) with similar sequences that are selectively expressed in cortical/hippocampal neurons or striatal neurons, respectively. Finally, phosphatase activity can be controlled by redox mechanisms such as demonstrated for PP2B. Overall, these multiple mechanisms represent an intricate means of tightly regulating the activity, substrate specificity and intracellular localization of protein phosphatases, making them highly selective.

The role of protein phosphatases in the cascade of events triggered during excitotoxic cell death has not been extensively studied, but some protein phosphatases, such as  $\text{Ca}^{2+}$ -dependent calcineurin, were found to contribute to excitotoxicity (because its inhibition is neuroprotective [28]). However, recent findings have indicated that protein phosphatases are implicated in both excitotoxic and cell survival mechanisms, depending on the timing of their activation, the nature and extent of the insult etc. These findings have prompted interest in studying their role as endogenous neuroprotective molecules and, in turn, considering their use as potential drug targets for

the treatment of disorders involving excitotoxicity and neuronal cell death [8, 29, 30].

### Events underlying excitotoxicity

Excitotoxicity is a complex process initiated when neuronal receptors for excitatory neurotransmitters are excessively activated during traumatic events such as cerebral ischemia, brain injury or seizure [31, 32]. Since several of the protein phosphatases discussed here might be neuroprotective by decreasing processes leading to excitotoxic cell death, the main aspects of this process will be reviewed. Excitotoxicity is triggered by energy and oxygen deprivation, and disruption of ionic homeostasis [33]. Under these deleterious conditions, neurons strongly depolarize, which leads to an excessive entry of calcium through calcium-permeant channels such as voltage-dependent calcium channels, channels associated with ionotropic glutamate receptors such as the NMDA receptor [34], transient receptor potential channels [35] and acid-sensing channels [36]. The NMDA receptor is recognized as one of the major mediators of calcium influx, triggering excitotoxic cell death in numerous neurological disorders [1, 37, 38]. As following hypoxia [39], oxygen-glucose deprivation enhances currents through NMDA receptors in hippocampal CA1 pyramidal neurons, but this does not occur in CA3 pyramidal neurons [P. Benquet, C. E. Gee and U. Gerber, unpublished observations]. Transient forebrain ischemia also increases NMDA receptor currents in CA1, leading to selective cell death of these neurons [40]. NMDA receptors are regulated by protein phosphorylation and are thus a central target of kinases and phosphatases during both excitotoxicity and cell survival [41]. Further to extracellular calcium entry, calcium release from endoplasmic reticulum stores contributes to massively increasing the level of intracellular calcium during excitotoxicity. Excessive activation of 1,4,5-inositol-trisphosphate receptors ( $\text{IP}_3$ -Rs) by  $\text{IP}_3$  leads to depletion of these  $\text{Ca}^{2+}$  stores and triggers neuronal death through both necrosis and apoptosis [42].

In addition to calcium entry, the production of reactive oxygen species exacerbates excitotoxic cell damage [32, 38], possibly by enhancing the activity of protein kinases or decreasing the activity of protein phosphatases [43]. The NMDA receptor is closely linked to the neuronal enzyme nitric oxide synthase (NOS) via PSD-95 interactions. Calcium entering through NMDA receptors stimulates NO production by NOS, which is neurotoxic at high levels [44, 45]. This observation may explain why calcium entering through NMDA receptors is more neurotoxic than calcium entering through voltage-dependent calcium channels or non-NMDA ionotropic glutamate receptors [46].

The induction of ischemic insult is accompanied by an impairment of mitochondrial functions, a decrease in the concentration of ATP and glucose, an accumulation of lactate and often also the initiation of inflammatory responses. Neurons within the injury core may then undergo apoptotic cell death or die as a result of necrosis [33]. A substantial number of neurons in regions adjacent to the injury core (the penumbra) may also be affected and die by programmed cell death, which contributes to a significant loss of neurological functions. Nevertheless, the viability of neurons in the penumbra is generally better than in the core, and therefore these neurons have a higher potential for preservation by appropriate intervention. Importantly, the occurrence of an excitotoxic event is accompanied by the activation of endogenous cell survival pathways that counteract cell death pathways. Mechanistically, excitotoxic events engage many of the intracellular molecules that mediate neuronal signalling in physiological conditions. These molecules intervene in two different ways: either they contribute to damage and promote neuronal death, or they counteract damage and sustain cell survival. Clearly, several individual molecules can take part in both processes depending on the type and level of injury, the homeostatic state of the injured cell and the timing after injury. Tyrosine and Ser/Thr protein phosphatases in particular play an active role in both processes and can have excitotoxic and neuroprotective functions. For instance, dramatic changes in phosphorylation/dephosphorylation of many proteins have been demonstrated during global ischemia and subsequent brain reperfusion. We will focus in the following section primarily on protein phosphatases with potential neuroprotective functions.

### Protein phosphatases that may be neuroprotective

#### Tyrosine phosphatases

Several protein phosphatases have been found to take part in processes that counteract excitotoxic or other insults and therefore may function as neuroprotectants. Possible neuroprotective candidates include the tyrosine phosphatases striatal-enriched phosphatase (STEP), the SH2-containing tyrosine phosphatases SHP1, SHP2 and protein tyrosine phosphatase alpha (PTP $\alpha$ ). PTP $\alpha$  may also promote neurotoxicity as has been shown for the tyrosine phosphatase phosphatase and tensin homolog deleted from chromosome 10 (PTEN). In trauma or disorders such as cerebral ischemia [47, 48], epileptiform activity [49, 50] or Alzheimer's disease [51], increased tyrosine phosphorylation mediated by Src or Fyn kinases is suggested to promote neuronal cell death.

Endogenous pathways and mechanisms involving protein phosphatases have evolved to counteract the negative effects of hyperphosphorylation. Because of its association

with the NMDA receptor complex, the tyrosine phosphatase STEP, especially its large isoform STEP<sub>61</sub>, is poised to fulfill such a function by opposing the potentiating effects of Src family kinase phosphorylation on NMDA receptor function [52]. In spite of its name, STEP is expressed in many regions of the brain, including the basal ganglia, striatum, cortex and hippocampus. It is composed of four isoforms, a large membrane-bound form (STEP<sub>61</sub>) and three lower molecular weight cytosolic isoforms [53]. Following transient global ischemia, STEP immunoreactivity increases in glia, specifically in regions where neurons undergo cell death [54]. In neurons, STEP dephosphorylates and inactivates several targets, including the Src family kinase Fyn [55] and ERK (extracellular signal-related kinase) [56]. These targets of STEP have also been implicated in neuronal death. During forebrain hypoxia/ischemia, STEP<sub>61</sub> is cleaved and its catalytic domain is released into the cytosol as a small molecular weight isoform (STEP<sub>33</sub>) [57]. It is not clear whether STEP<sub>33</sub> maintains its catalytic activity and whether its separation from the NMDA receptor complex changes its availability; however, STEP appears to be a good candidate for reversing Src-dependent enhancement of NMDA currents. It is possible that its cleavage is prevented in ischemia-resistant neurons and may contribute to the tyrosine phosphatase-dependent maintenance of NMDA currents in protected CA3 cells. Interestingly, STEP is activated by dephosphorylation by the calcium-dependent Ser/Thr protein phosphatase calcineurin [56], which is more abundant in CA3 neurons, and therefore STEP may be part of a complex mechanism counteracting Src-dependent enhancement of NMDA responses [52].

Besides STEP, several other protein phosphatases also control Src activity and Src-mediated phosphorylation of targets involved in excitotoxicity. Src activation depends on the phosphorylation/dephosphorylation of two tyrosine residues, Y527 and Y416, with Y527 phosphorylation being inhibitory and Y416 phosphorylation being excitatory. The tyrosine phosphatases SHP2 and PTP $\alpha$  increase Src activity by promoting Y527 dephosphorylation either indirectly for SHP2 by reducing the interaction of Src with the tyrosine kinase Csk [58] or directly for PTP $\alpha$  [59]. Despite this function, however, SHP2 was found to promote cell survival by mechanisms that are not well understood but that may involve enhancement of neurotrophin signalling [60–62]. SHP2 is expressed in various neurons in human and mouse adult brain [63, 64] and is localized in pre- and postsynaptic membranes [65] and mitochondria [66]. It is essential during development and its loss by knockout is lethal. Its downregulation, achieved by expression of a dominant negative in the adult brain, increases the sensitivity to focal cerebral ischemia/reperfusion injury [67]. Consistently, in a model of CNS injury using nitric oxide, SHP2 inhibition was found to reduce survival of

primary cultured neurons and increase caspase activation, a marker of programmed cell death [68]. It may have a neuroprotective role as its level of activity increases in reactive glia following permanent focal ischemia [64]. The targets of SHP2 have not all been identified, but tyrosine kinase-dependent signalling pathways are positively regulated by SHP2 through, for instance, dephosphorylation and inactivation of the receptor tyrosine kinase inhibitor Sprouty [69]. SHP2 itself is also activated by tyrosine phosphorylation [70] and therefore appears as a central component of feedback and crosstalk mechanisms between multiple signalling pathways.

SHP1 is a tyrosine phosphatase with SH2 domains that is upregulated in rodent brain following insult. SHP1 is found in some neurons but is primarily expressed in glial cells such that loss of SHP1 leads to dysmyelination in the central nervous system (CNS) [71]. In young mice, SHP1 is upregulated by permanent focal cerebral ischemia in non-dividing astrocytes and microglia and appears to limit their activation, thereby reducing the potential for glial scar formation [72]. The production of some anti- and pro-inflammatory cytokines following deafferentation is also decreased and increased, respectively, in SHP1 mutants, suggesting that a further neuroprotective action of SHP1 is the reduction of the inflammatory response triggered by glial activation [73].

PTP $\alpha$  activity regulates the activity of neuronal Kv1.2 potassium channels and NMDA receptors. Carbachol activates m1 muscarinic receptors, resulting in tyrosine phosphorylation that correlates with the suppression of Kv1.2 channel currents [74]. PTP $\alpha$  activity is increased by carbachol via tyrosine phosphorylation. Carbachol stimulation additionally promotes the association of phosphorylated PTP $\alpha$  with phosphorylated Kv1.2 channels, resulting in dephosphorylation, which reverses the suppression of currents [75]. Increasing conductance of potassium channels to hyperpolarize neurons is an important mechanism to limit calcium entry during excitotoxicity. Whether PTP $\alpha$  activity plays a role in maintaining potassium channel activity under excitotoxic conditions has not been explored. However, it is known that oxidative stress promotes a conformational change in PTP $\alpha$  dimers that reduces its activity and would be maladaptive in this context [76, 77]. Another effect of PTP $\alpha$  activity is to activate Src family kinases and increase currents through NMDA receptors [78]. An increase in this property of PTP $\alpha$  during insults would be expected to exacerbate injury; thus it is unclear whether promoting PTP $\alpha$  activity would be neuroprotective or whether the reduction of PTP $\alpha$  activity by reactive oxygen species would instead be neuroprotective.

PTEN is a dual-specificity kinase that dephosphorylates phosphotyrosine and phosphoserine/threonine-containing substrates [79]. In contrast to most of the other phosphatases mentioned in this review, downregulation of

PTEN is neuroprotective against glutamate excitotoxicity [80] and transient focal ischemia [81]. PTEN interacts with NR1/NR2B-containing NMDA receptors [82]. Knock-down of PTEN with small interfering RNA (siRNA) decreases currents through the extrasynaptic NR1/NR2B-containing NMDA receptors by decreasing both the channel-open probability and the surface expression of the channels. Neuroprotection against transient global ischemia-induced neuronal death conferred by PTEN downregulation depends on the resulting increase in Akt activity and the decrease in NMDA receptor currents [82].

### Ser/Thr phosphatases

In parallel to Tyr protein kinases and protein phosphatases, numerous Ser/Thr kinases and phosphatases are activated during excitotoxic and cell survival events and participate in controlling the outcome of insults to the brain. Protein kinases such as the Ca<sup>2+</sup>/calmodulin-dependent protein kinase CaMKII, protein kinase C (PKC) and A (PKA), and Cdk5 are recruited. For instance, phosphorylation by Cdk5 is activated in CA1 hippocampal neurons after transient forebrain ischemia and targets, in particular, the NR2A subunit of the NMDA receptor [40]. Such phosphorylation is detrimental to tissue because its prevention by inhibition of endogenous Cdk5 or by blockade of its interaction with NR2A protects CA1 pyramidal neurons from ischemic insult. This mechanism may contribute to the selective vulnerability of CA1 neurons to ischemia. Concomitantly to kinases, several Ser/Thr protein phosphatases, such as PP1, calcineurin and PP2A are activated to counteract the effect of kinases. In the rat hippocampus in vivo, inhibition of PP1 by okadaic acid increases NMDA receptor phosphorylation and induces a marked degeneration of CA1 hippocampal neurons, suggesting a positive effect of PP1 on cell survival [83]. Likewise, in vitro, PP1 inhibition mimics the physiological effects of hypoxia and severe hypoxia in epithelial cell culture and is accompanied by downregulation of PP1 $\gamma$  expression. The drop in PP1 leads to hyperphosphorylation of several PP1 targets, including the transcription factor CREB [84], followed by ubiquitination and proteosomal degradation of CREB, a final phase in the expression of hypoxic damage. During ischemia, PP1 may also control the formation of clusters of CaMKII in synaptic terminals, which represents a cellular strategy to prevent CaMKII-mediated phosphorylation during episodes of Ca<sup>2+</sup> overload [85].

Despite its recognized role as a major mediator of excitotoxicity and neuronal cell death, calcineurin is also involved in mechanisms of neuroprotection [86]. Following transient forebrain ischemia, calcineurin activity decreases in the hippocampus, but interestingly not to the same extent in CA1 and CA3 neurons. While it decreases

only transiently in the CA3 region, it does so persistently in CA1 neurons. This may result from its larger concentration in CA3 versus CA1 neurons under normal conditions, a difference that may maintain homeostatic levels of NMDA receptor phosphorylation. It may also help reverse ischemia-induced NMDA hyperactivation to prevent excitotoxicity. Calcineurin can efficiently downregulate NMDA receptor activity by dephosphorylating NR2A and desensitizing the receptor, a mechanism known to be neuroprotective [87]. It can also inactivate L-type  $\text{Ca}^{2+}$  channels and thereby diminish  $\text{Ca}^{2+}$  entry [21, 22].

Another target of calcineurin involved in neuroprotection is Bcl-2, a critical regulator of apoptosis. During the early phase of hypoxia/aglycemia in brain slices, calcineurin and Bcl-2 interact, and this interaction triggers the shuttling of calcineurin to intracellular substrates, in particular the  $\text{IP}_3$ -Rs [88, 89]. Shuttling of cellular proteins to their substrates by Bcl-2 is actually a general anti-apoptotic mechanism [90]. By dephosphorylating  $\text{IP}_3$ -Rs, calcineurin inhibits excitation-induced calcium release from internal stores, thereby preventing further increase in calcium in the cell and the depletion of calcium stores [91]. Calcineurin-induced desensitization of  $\text{IP}_3$ -Rs may be an important neuronal defense system against excitotoxicity.

Calcineurin is involved in specific mechanisms of neuroprotection such as those induced by nicotine. Nicotine pretreatment is effective in reducing cell death in cortical neurons subjected to glutamate overactivation. This protective function is mediated by activation of  $\alpha 7$ - and  $\beta 2$ -containing nicotinic acetylcholine receptors followed by  $\text{Ca}^{2+}$  influx and recruitment of calcineurin [92]. Nicotine-mediated effects are abolished when calcineurin is inhibited before glutamate excitotoxicity. However, when inhibited only after glutamate overload, the neurons are preserved. This observation is consistent with the demonstrated neuroprotective effect of the inhibition of calcineurin by immunosuppressants such as cyclosporin A and FK506 [86]. It illustrates the dual role of calcineurin in excitotoxic cell death, depending on whether it is activated or inhibited, and whether this occurs before, during or after insult. Thus, calcineurin activation before excitotoxicity is neuroprotective, whereas its activation after excitotoxicity promotes damage, in which case calcineurin blockade is neuroprotective. This duality is reminiscent of the binary nature of the activation of the NMDA receptor itself that, depending on its level, either mediates excitotoxic cell death or promotes activity-dependent cell survival. Thus, strong NMDA receptor activation by high concentrations of NMDA induces excitotoxicity accompanied by calcineurin activation and transient increase in the phosphorylation of the transcription factor CREB. By contrast, non-toxic levels of NMDA mimic endogenous synaptic activity without activating calcineurin but with sustained CREB phosphorylation [93]. The mechanisms and targets involved in

calcineurin signalling during excitotoxic/neuroprotective events are thus variable, depending on the nature and extent of the injury, the temporal stage, the affected brain area and the cell type.

Finally, the apparent discrepancy between the demonstrated neuroprotective property of calcineurin inhibitors such as the immunosuppressants CsA and FK506, and the potential neuroprotective function of calcineurin itself, may be accounted for by indirect mechanisms of drug action. For instance, CsA acts through inhibition of the immunophilin cyclophilin D, which itself can prevent mitochondrial damage [94]. Also FK506, in addition to inhibiting calcineurin, activates heat shock proteins and is therefore not specific [95]. Another possible mechanism of immunosuppressant-mediated neuroprotection may be via inhibition of astrocyte and microglial activation and proliferation, and reduction of the inflammatory response [28].

### Search for endogenous mechanisms of neuroprotection

As CA1 pyramidal neurons are more sensitive to excitotoxic injury than CA3 pyramidal neurons, it is of interest to exploit this property to study the mechanisms underlying excitotoxicity and endogenous neuroprotective mechanisms. In an attempt to identify the molecular targets potentially involved in such mechanisms, a recent study compared the profile of gene expression in microdissected human CA1 versus CA3 pyramidal neurons. At least 60 genes were found to be differentially expressed at the mRNA level in these neurons (a minimum 1.7-fold enrichment) [96]. Among them, two Ser/Thr kinases, JNK and JNK2, involved in apoptotic cell death were more highly expressed in CA1 pyramidal neurons. Blockade of JNK activation after cerebral ischemia was found to be neuroprotective, suggesting that JNK promotes excitotoxicity [97, 98], which is consistent with the increased level of JNK expression observed after ischemia [99, 100]. However, this increase may be counteracted by protein phosphatases, in particular the dual-specificity protein phosphatase MKP (MAP kinase phosphatase), which was found to dephosphorylate and inactivate JNK [101]. However, MKP activity was found to decrease with hypoxia. Ultimately, the net balance between this kinase/phosphatase interplay determines whether cell death or survival is favoured.

Another molecule more predominantly expressed in CA1 than in CA3 is the receptor-like tyrosine phosphatase PTPro. In brain, PTPro is highest during development, where it is postulated to play a role in axogenesis [102, 103]. In adult brain, its levels remain high in CA1 neurons and certain other cell types [104]. The function of PTPro has not been explored in the adult brain or during excitotoxic injury, but it may be important.

As previously mentioned, currents through NMDA receptors are enhanced in several models of ischemic insult. In vitro oxygen-glucose deprivation rapidly enhances NMDA currents in CA1 pyramidal neurons, but not in the less vulnerable CA3 pyramidal neurons [P. Benquet, C. E. Gee and U. Gerber, unpublished observations]. In CA3 pyramidal neurons, inhibiting tyrosine phosphatases unmasks a similar tyrosine kinase-dependent enhancement of NMDA currents and exacerbates ensuing cell death, suggesting that tyrosine phosphatase activity contributes to protection of these neurons. Whether enhancing this phosphatase activity in more vulnerable neurons will be neuroprotective warrants further investigation.

### Conclusions and perspectives

At present the possible role of protein phosphatases in either preventing or promoting excitotoxic mechanisms is not fully understood. As their modes of action are complex, their effects may be diametrically opposed, depending on the type and extent of injury, the area of the brain and cell type injured, and the physiological state of the cell. Concerted efforts will be required to elucidate the mechanisms through which they act. In addition to the excitatory mechanisms delineated above, non-excitatory processes may also mediate glutamate excitotoxicity and cell death, as recently shown in retinal ganglion cells [105]. These mechanisms involve kainate-type ionotropic glutamate receptors and calcium influx but no depolarization. Protein phosphatases are also implicated in these processes. For instance, cellular damage induced by kainate is reduced by the calcineurin inhibitor CsA. However, here again little is known about the mechanisms involved. Thus, overall, better knowledge of the mechanisms of excitotoxicity will be indispensable in developing new approaches for the treatment of brain trauma and disorders associated with neuronal cell death, and should allow the design of novel neuroprotective agents [106].

*Acknowledgements.* We thank Eva Hochreutener for graphical work and Urs Gerber and the anonymous reviewers for their critical reading. C.G. is supported by the National Center for Competence in Research 'Neural Plasticity and Repair'. The lab of I.M.M. is funded by the Swiss Federal Institute of Technology, the University of Zurich, the National Center for Competence in Research 'Neural Plasticity and Repair', the Swiss National Science Foundation, the Human Frontier Science Program, EMBO, Novartis Research Foundation, Roche Research Foundation and UBS bank.

- 1 Lipton S. A. (2004) Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. *J. Alzheimers Dis.* **6**: S61–S74
- 2 Koller W. C. and Cersosimo M. G. (2004) Neuroprotection in Parkinson's disease: an elusive goal. *Curr. Neurol. Neurosci. Rep.* **4**: 277–283
- 3 Facheris M., Beretta S. and Ferrarese C. (2004) Peripheral markers of oxidative stress and excitotoxicity in neurodegenerative disorders: tools for diagnosis and therapy? *J. Alzheimers Dis.* **6**: 177–184
- 4 Gardian G. and Vecsei L. (2004) Huntington's disease: pathomechanism and therapeutic perspectives. *J. Neural Transm.* **111**: 1485–1494
- 5 Hooft v. H., Sauer W. H., Bombrun A. and Swinnen D. (2004) Prospects for inhibitors of protein tyrosine phosphatase 1B as antidiabetic drugs. *J. Med. Chem.* **47**: 4142–4146
- 6 Smukste I. and Stockwell B. R. (2003) Restoring functions of tumor suppressors with small molecules. *Cancer Cell* **4**: 419–420
- 7 Tartaglia M., Niemeyer C. M., Shannon K. M. and Loh M. L. (2004) SHP-2 and myeloid malignancies. *Curr. Opin. Hematol.* **11**: 44–50
- 8 Stiles B., Groszer M., Wang S., Jiao J. and Wu H. (2004) PTEless means more. *Dev. Biol.* **273**: 175–184
- 9 Smith M., Filipek P. A., Wu C., Bocian M., Hakim S., Modahl C. et al. (2000) Analysis of a 1-megabase deletion in 15q22-q23 in an autistic patient: identification of candidate genes for autism and of homologous DNA segments in 15q22-q23 and 15q11-q13. *Am. J. Med. Genet.* **96**: 765–770
- 10 Bottini N., Bottini E., Gloria-Bottini F. and Mustelin T. (2002) Low-molecular-weight protein tyrosine phosphatase and human disease: in search of biochemical mechanisms. *Arch. Immunol. Ther. Exp. (Warsz.)* **50**: 95–104
- 11 Minassian B. A. (2001) Lafora's disease: towards a clinical, pathologic and molecular synthesis. *Pediatr. Neurol.* **25**: 21–29
- 12 Zhen X., Torres C., Cai G. and Friedman E. (2002) Inhibition of protein tyrosine/mitogen-activated protein kinase phosphatase activity is associated with D2 dopamine receptor supersensitivity in a rat model of Parkinson's disease. *Mol. Pharmacol.* **62**: 1356–1363
- 13 Alonso A., Sasin J., Bottini N., Friedberg I., Friedberg I., Osterman A. et al. (2004) Protein tyrosine phosphatases in the human genome. *Cell* **117**: 699–711
- 14 Andersen J. N., Jansen P. G., Echwald S. M., Mortensen O. H., Fukada T., Del Vecchio R. et al. (2004) A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. *FASEB J.* **18**: 8–30
- 15 Zhang Z. Y. (2002) Protein tyrosine phosphatases: structure and function, substrate specificity and inhibitor development. *Annu. Rev. Pharmacol. Toxicol.* **42**: 209–234
- 16 Zhang Z. Y. (2003) Mechanistic studies on protein tyrosine phosphatases. *Prog. Nucleic Acid Res. Mol. Biol.* **73**: 171–220
- 17 Li X., Oghi K. A., Zhang J., Kronen A., Bush K. T., Glass C. K. et al. (2003) Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. *Nature* **426**: 247–254
- 18 Denu J. M. and Dixon J. E. (1998) Protein tyrosine phosphatases: mechanisms of catalysis and regulation. *Curr. Opin. Chem. Biol.* **2**: 633–641
- 19 Zhang Z. Y. (1998) Protein-tyrosine phosphatases: biological function, structural characteristics and mechanism of catalysis. *Crit. Rev. Biochem. Mol. Biol.* **33**: 1–52
- 20 Thomas M. L. and Brown E. J. (1999) Positive and negative regulation of Src-family membrane kinases by CD45. *Immunol. Today* **20**: 406–411
- 21 Price N. E. and Mumby M. C. (1999) Brain protein serine/threonine phosphatases. *Curr. Opin. Neurobiol.* **9**: 336–342
- 22 Rusnak F. and Mertz P. (2000) Calcineurin: form and function. *Physiol. Rev.* **80**: 1483–1521
- 23 Wong W. and Scott J. D. (2004) AKAP signalling complexes: focal points in space and time. *Nat. Rev. Mol. Cell Biol.* **5**: 959–970
- 24 Smith F. D., Oxford G. S. and Milgram S. L. (1999) Association of the D2 dopamine receptor third cytoplasmic loop with



- spinophilin, a protein phosphatase-1-interacting protein. *J. Biol. Chem.* **274**: 19894–19900
- 25 Richman J. G., Brady A. E., Wang Q., Hensel J. L., Colbran R. J. and Limbird L. E. (2001) Agonist-regulated interaction between alpha2-adrenergic receptors and spinophilin. *J. Biol. Chem.* **276**: 15003–15008
- 26 Burnett P. E., Blackshaw S., Lai M. M., Qureshi I. A., Burnett A. F., Sabatini D. M. et al. (1998) Neurabin is a synaptic protein linking p70 S6 kinase and the neuronal cytoskeleton. *Proc. Natl. Acad. Sci. USA* **95**: 8351–8356
- 27 Katayose Y., Li M., Al Murrani S. W., Shenolikar S. and Damuni Z. (2000) Protein phosphatase 2A inhibitors, I(1)-(PP2A) and I(2)(PP2A), associate with and modify the substrate specificity of protein phosphatase 1. *J. Biol. Chem.* **275**: 9209–9214
- 28 Kaminska B., Gaweda-Walerych K. and Zawadzka M. (2004) Molecular mechanisms of neuroprotective action of immunosuppressants – facts and hypotheses. *J. Cell Mol. Med.* **8**: 45–58
- 29 Hoffman B. T., Nelson M. R., Burdick K. and Baxter S. M. (2004) Protein tyrosine phosphatases: strategies for distinguishing proteins in a family containing multiple drug targets and anti-targets. *Curr. Pharm. Des.* **10**: 1161–1181
- 30 Umezawa K., Kawakami M. and Watanabe T. (2003) Molecular design and biological activities of protein-tyrosine phosphatase inhibitors. *Pharmacol. Ther.* **99**: 15–24
- 31 Liou A. K., Clark R. S., Henshall D. C., Yin X. M. and Chen J. (2003) To die or not to die for neurons in ischemia, traumatic brain injury and epilepsy: a review on the stress-activated signaling pathways and apoptotic pathways. *Prog. Neurobiol.* **69**: 103–142
- 32 Sapolsky R. M. (2001) Cellular defenses against excitotoxic insults. *J. Neurochem.* **76**: 1601–1611
- 33 Vajda F. J. (2002) Neuroprotection and neurodegenerative disease. *J. Clin. Neurosci.* **9**: 4–8
- 34 Lipton P. (1999) Ischemic cell death in brain neurons. *Physiol. Rev.* **79**: 1431–1568
- 35 Aarts M., Ihara K., Wei W. L., Xiong Z. G., Arundine M., Cerwinski W. et al. (2003) A key role for TRPM7 channels in anoxic neuronal death. *Cell* **115**: 863–877
- 36 Xiong Z. G., Zhu X. M., Chu X. P., Minami M., Hey J., Wei W. L. et al. (2004) Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels. *Cell* **118**: 687–698
- 37 Waxman E. A. and Lynch D. R. (2005) N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. *Neuroscientist* **11**: 37–49
- 38 Arundine M. and Tymianski M. (2004) Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. *Cell. Mol. Life Sci.* **61**: 657–668
- 39 Crepel V., Hammond C., Chinea P., Diabira D. and Ben Ari Y. (1993) A selective LTP of NMDA receptor-mediated currents induced by anoxia in CA1 hippocampal neurons. *J. Neurophysiol.* **70**: 2045–2055
- 40 Wang J., Liu S., Fu Y., Wang J. H. and Lu Y. (2003) Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors. *Nat. Neurosci.* **6**: 1039–1047
- 41 Salter M. W. and Kalia L. V. (2004) Src kinases: a hub for NMDA receptor regulation. *Nat. Rev. Neurosci.* **5**: 317–328
- 42 Patterson R. L., Boehning D. and Snyder S. H. (2004) Inositol 1,4,5-trisphosphate receptors as signal integrators. *Annu. Rev. Biochem.* **73**: 437–465
- 43 Klann E. and Thiels E. (1999) Modulation of protein kinases and protein phosphatases by reactive oxygen species: implications for hippocampal synaptic plasticity. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **23**: 359–376
- 44 Lipton S. A. (1999) Neuronal protection and destruction by NO. *Cell Death. Differ.* **6**: 943–951
- 45 Nelson E. J., Connolly J. and McArthur P. (2003) Nitric oxide and S-nitrosylation: excitotoxic and cell signaling mechanism. *Biol. Cell* **95**: 3–8
- 46 Sattler R., Charlton M. P., Hafner M. and Tymianski M. (1998) Distinct influx pathways, not calcium load, determine neuronal vulnerability to calcium neurotoxicity. *J. Neurochem.* **71**: 2349–2364
- 47 Ohtsuki T., Matsumoto M., Kitagawa K., Mabuchi T., Mandai K., Matsushita K. et al. (1996) Delayed neuronal death in ischemic hippocampus involves stimulation of protein tyrosine phosphorylation. *Am. J. Physiol.* **271**: C1085–C1097
- 48 Paul R., Zhang Z. G., Eliceiri B. P., Jiang Q., Boccia A. D., Zhang R. L. et al. (2001) Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. *Nat. Med.* **7**: 222–227
- 49 Chun J. T., Crispino M. and Tocco G. (2004) The dual response of protein kinase Fyn to neural trauma: early induction in neurons and delayed induction in reactive astrocytes. *Exp. Neurol.* **185**: 109–119
- 50 Sanna P. P., Berton F., Cammalleri M., Tallent M. K., Siggins G. R., Bloom F. E. et al. (2000) A role for Src kinase in spontaneous epileptiform activity in the CA3 region of the hippocampus. *Proc. Natl. Acad. Sci. USA* **97**: 8653–8657
- 51 Lee G., Thangavel R., Sharma V. M., Litersky J. M., Bhaskar K., Fang S. M. et al. (2004) Phosphorylation of tau by fyn: implications for Alzheimer's disease. *J. Neurosci.* **24**: 2304–2312
- 52 Pelkey K. A., Askalan R., Paul S., Kalia L. V., Nguyen T. H., Pitcher G. M. et al. (2002) Tyrosine phosphatase STEP is a tonic brake on induction of long-term potentiation. *Neuron* **34**: 127–138
- 53 Boulanger L. M., Lombroso P. J., Raghunathan A., During M. J., Wahle P. and Naegele J. R. (1995) Cellular and molecular characterization of a brain-enriched protein tyrosine phosphatase. *J. Neurosci.* **15**: 1532–1544
- 54 Hasegawa S., Morioka M., Goto S., Korematsu K., Okamura A., Yano S. et al. (2000) Expression of neuron specific phosphatase, striatal enriched phosphatase (STEP) in reactive astrocytes after transient forebrain ischemia. *Glia* **29**: 316–329
- 55 Nguyen T. H., Liu J. and Lombroso P. J. (2002) Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420. *J. Biol. Chem.* **277**: 24274–24279
- 56 Paul S., Nairn A. C., Wang P. and Lombroso P. J. (2003) NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling. *Nat. Neurosci.* **6**: 34–42
- 57 Gurd J. W., Bissoon N., Nguyen T. H., Lombroso P. J., Rider C. C., Beesley P. W. et al. (1999) Hypoxia-ischemia in perinatal rat brain induces the formation of a low molecular weight isoform of striatal enriched tyrosine phosphatase (STEP). *J. Neurochem.* **73**: 1990–1994
- 58 Zhang S. Q., Yang W., Kontaridis M. I., Bivona T. G., Wen G., Araki T. et al. (2004) Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. *Mol. Cell* **13**: 341–355
- 59 Brandt D. T., Goerke A., Heuer M., Gimona M., Leitges M., Kremmer E. et al. (2003) Protein kinase C delta induces Src kinase activity via activation of the protein tyrosine phosphatase PTP alpha. *J. Biol. Chem.* **278**: 34073–34078
- 60 Okada N., Wada K., Goldsmith B. A. and Koizumi S. (1996) SHP-2 is involved in neurotrophin signaling. *Biochem. Biophys. Res. Commun.* **229**: 607–611
- 61 Takai S., Yamada M., Araki T., Koshimizu H., Nawa H. and Hatanaka H. (2002) Shp-2 positively regulates brain-derived neurotrophic factor-promoted survival of cultured ventral mesencephalic dopaminergic neurons through a brain immunoglobulin-like molecule with tyrosine-based activation motifs/Shp substrate-1. *J. Neurochem.* **82**: 353–364
- 62 Araki T., Yamada M., Ohnishi H., Sano S., Uetsuki T. and Hatanaka H. (2000) Shp-2 specifically regulates several tyrosine-phosphorylated proteins in brain-derived neurotrophic factor signaling in cultured cerebral cortical neurons. *J. Neurochem.* **74**: 659–668

- 63 Reeves S. A., Ueki K., Sinha B., Difiglia M. and Louis D. N. (1996) Regional expression and subcellular localization of the tyrosine-specific phosphatase SH-PTP2 in the adult human nervous system. *Neuroscience* **71**: 1037–1042
- 64 Servidei T., Bhide P. G., Huang Z., Moskowitz M. A., Harsh G. and Reeves S. A. (1998) The protein tyrosine phosphatase SHP-2 is expressed in glial and neuronal progenitor cells, postmitotic neurons and reactive astrocytes. *Neuroscience* **82**: 529–543
- 65 Suzuki T., Matozaki T., Mizoguchi A. and Kasuga M. (1995) Localization and subcellular distribution of SH-PTP2, a protein-tyrosine phosphatase with Src homology-2 domains, in rat brain. *Biochem. Biophys. Res. Commun.* **211**: 950–959
- 66 Salvi M., Stringaro A., Brunati A. M., Agostinelli E., Arancia G., Clari G. et al. (2004) Tyrosine phosphatase activity in mitochondria: presence of Shp-2 phosphatase in mitochondria. *Cell Mol. Life Sci.* **61**: 2393–2404
- 67 Aoki Y., Huang Z., Thomas S. S., Bhide P. G., Huang L., Moskowitz M. A. et al. (2000) Increased susceptibility to ischemia-induced brain damage in transgenic mice overexpressing a dominant negative form of SHP2. *FASEB J.* **14**: 1965–1973
- 68 Chong Z. Z., Lin S. H., Kang J. Q. and Maiese K. (2003) The tyrosine phosphatase SHP2 modulates MAP kinase p38 and caspase 1 and 3 to foster neuronal survival. *Cell. Mol. Neurobiol.* **23**: 561–578
- 69 Hanafusa H., Torii S., Yasunaga T., Matsumoto K. and Nishida E. (2004) Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty. *J. Biol. Chem.* **279**: 22992–22995
- 70 Vogel W., Lammers R., Huang J. and Ullrich A. (1993) Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. *Science* **259**: 1611–1614
- 71 Massa P. T., Wu C. and Fecenko-Tacka K. (2004) Dysmyelination and reduced myelin basic protein gene expression by oligodendrocytes of SHP-1-deficient mice. *J. Neurosci. Res.* **77**: 15–25
- 72 Wishcamper C. A., Brooks D. M., Douglas C. J. and Lurie D. I. (2003) Focal cerebral ischemia upregulates SHP-1 in reactive astrocytes in juvenile mice. *Brain Res.* **974**: 88–98
- 73 Zhao J. and Lurie D. I. (2004) Loss of SHP-1 phosphatase alters cytokine expression in the mouse hindbrain following cochlear ablation. *Cytokine* **28**: 1–9
- 74 Huang X. Y., Morielli A. D. and Peralta E. G. (1993) Tyrosine kinase-dependent suppression of a potassium channel by the G protein-coupled m1 muscarinic acetylcholine receptor. *Cell* **75**: 1145–1156
- 75 Tsai W., Morielli A. D., Cachero T. G. and Peralta E. G. (1999) Receptor protein tyrosine phosphatase alpha participates in the m1 muscarinic acetylcholine receptor-dependent regulation of Kv1.2 channel activity. *EMBO J.* **18**: 109–118
- 76 Blanchetot C., Tertoolen L. G. and den Hertog J. (2002) Regulation of receptor protein-tyrosine phosphatase alpha by oxidative stress. *EMBO J.* **21**: 493–503
- 77 van der Wijk T., Blanchetot C., Overvoorde J. and den Hertog J. (2003) Redox-regulated rotational coupling of receptor protein-tyrosine phosphatase alpha dimers. *J. Biol. Chem.* **278**: 13968–13974
- 78 Lei G., Xue S., Chery N., Liu Q., Xu J., Kwan C. L. et al. (2002) Gain control of N-methyl-D-aspartate receptor activity by receptor-like protein tyrosine phosphatase alpha. *EMBO J.* **21**: 2977–2989
- 79 Myers M. P., Stolarov J. P., Eng C., Li J., Wang S. I., Wigler M. H. et al. (1997) P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. *Proc. Natl. Acad. Sci. USA* **94**: 9052–9057
- 80 Gary D. S. and Mattson M. P. (2002) PTEN regulates Akt kinase activity in hippocampal neurons and increases their sensitivity to glutamate and apoptosis. *Neuromolecular Med.* **2**: 261–269
- 81 Lee J. H., Kim K. Y., Lee Y. K., Park S. Y., Kim C. D., Lee W. S. et al. (2004) Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats. *J. Pharmacol. Exp. Ther.* **308**: 896–903
- 82 Ning K., Pei L., Liao M., Liu B., Zhang Y., Jiang W. et al. (2004) Dual neuroprotective signaling mediated by downregulating two distinct phosphatase activities of PTEN. *J. Neurosci.* **24**: 4052–4060
- 83 Arias C., Montiel T., Pena F., Ferrera P. and Tapia R. (2002) Okadaic acid induces epileptic seizures and hyperphosphorylation of the NR2B subunit of the NMDA receptor in rat hippocampus in vivo. *Exp. Neurol.* **177**: 284–291
- 84 Taylor C. T., Furuta G. T., Synnestvedt K. and Colgan S. P. (2000) Phosphorylation-dependent targeting of cAMP response element binding protein to the ubiquitin/proteasome pathway in hypoxia. *Proc. Natl. Acad. Sci. USA* **97**: 12091–12096
- 85 Tao-Cheng J. H., Vinade L., Winters C. A., Reese T. S. and Dosemeci A. (2005) Inhibition of phosphatase activity facilitates the formation and maintenance of NMDA-induced calcium/calmodulin-dependent protein kinase II clusters in hippocampal neurons. *Neuroscience* **130**: 651–656
- 86 Morioka M., Fukunaga K., Hasegawa S., Okamura A., Korematsu K., Kai Y. et al. (1999) Activities of calcineurin and phosphatase 2A in the hippocampus after transient forebrain ischemia. *Brain Res.* **828**: 135–144
- 87 Wood A. M. and Bristow D. R. (1998) N-methyl-D-aspartate receptor desensitisation is neuroprotective by inhibiting glutamate-induced apoptotic-like death. *J. Neurochem.* **70**: 677–687
- 88 Erin N., Lehman R. A., Boyer P. J. and Billingsley M. L. (2003) In vitro hypoxia and excitotoxicity in human brain induce calcineurin-Bcl-2 interactions. *Neuroscience* **117**: 557–565
- 89 Erin N., Bronson S. K. and Billingsley M. L. (2003) Calcium-dependent interaction of calcineurin with Bcl-2 in neuronal tissue. *Neuroscience* **117**: 541–555
- 90 Reed J. C. (1997) Double identity for proteins of the Bcl-2 family. *Nature* **387**: 773–776
- 91 Cameron A. M., Steiner J. P., Roskams A. J., Ali S. M., Ronnett G. V. and Snyder S. H. (1995) Calcineurin associated with the inositol 1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca<sup>2+</sup> flux. *Cell* **83**: 463–472
- 92 Stevens T. R., Krueger S. R., Fitzsimonds R. M. and Picciotto M. R. (2003) Neuroprotection by nicotine in mouse primary cortical cultures involves activation of calcineurin and L-type calcium channel inactivation. *J. Neurosci.* **23**: 10093–10099
- 93 Lee B., Butcher G. Q., Hoyt K. R., Impey S. and Obrietan K. (2005) Activity-dependent neuroprotection and cAMP response element-binding protein (CREB): kinase coupling, stimulus intensity and temporal regulation of CREB phosphorylation at serine 133. *J. Neurosci.* **25**: 1137–1148
- 94 Uchino H., Ishii N. and Shibasaki F. (2003) Calcineurin and cyclophilin D are differential targets of neuroprotection by immunosuppressants CsA and FK506 in ischemic brain damage. *Acta Neurochir. Suppl.* **86**: 105–111
- 95 Klettner A. and Herdegen T. (2003) FK506 and its analogs – therapeutic potential for neurological disorders. *Curr. Drug Targets CNS Neurol. Disord.* **2**: 153–162
- 96 Torres-Munoz J. E., Van Waveren C., Keegan M. G., Bookman R. J. and Petito C. K. (2004) Gene expression profiles in microdissected neurons from human hippocampal subregions. *Brain Res. Mol. Brain Res.* **127**: 105–114
- 97 Borsello T., Clarke P. G., Hirt L., Vercelli A., Repici M., Schorderet D. F. et al. (2003) A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. *Nat. Med.* **9**: 1180–1186

- 98 Hirt L., Badaut J., Thevenet J., Granziera C., Regli L., Maurer F. et al. (2004) D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia. *Stroke* **35**: 1738–1743
- 99 Seta K. A., Kim R., Kim H. W., Millhorn D. E. and Beitner-Johnson D. (2001) Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. *J. Biol. Chem.* **276**: 44405–44412
- 100 Bernaudin M., Tang Y., Reilly M., Petit E. and Sharp F. R. (2002) Brain genomic response following hypoxia and reoxygenation in the neonatal rat. Identification of genes that might contribute to hypoxia-induced ischemic tolerance. *J. Biol. Chem.* **277**: 39728–39738
- 101 Hirsch D. D. and Stork P. J. (1997) Mitogen-activated protein kinase phosphatases inactivate stress-activated protein kinase pathways in vivo. *J. Biol. Chem.* **272**: 4568–4575
- 102 Beltran P. J., Bixby J. L. and Masters B. A. (2003) Expression of PTPRO during mouse development suggests involvement in axonogenesis and differentiation of NT-3 and NGF-dependent neurons. *J. Comp Neurol.* **456**: 384–395
- 103 Stepanek L., Sun Q. L., Wang J., Wang C. and Bixby J. L. (2001) CRYP-2/cPTPRO is a neurite inhibitory repulsive guidance cue for retinal neurons in vitro. *J. Cell Biol.* **154**: 867–878
- 104 Cheng J., Wu K., Armanini M., O'Rourke N., Dowbenko D. and Lasky L. A. (1997) A novel protein-tyrosine phosphatase related to the homotypically adhering kappa and mu receptors. *J. Biol. Chem.* **272**: 7264–7277
- 105 Shen W. and Slaughter M. M. (2002) A non-excitatory paradigm of glutamate toxicity. *J. Neurophysiol.* **87**: 1629–1634
- 106 Levi M. S. and Brimble M. A. (2004) A review of neuroprotective agents. *Curr. Med. Chem.* **11**: 2383–2397



To access this journal online:  
<http://www.birkhauser.ch>

---